SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ANRG -- Anergen -- new CEO big chance ?
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tonyt who wrote (74)2/10/1998 8:20:00 AM
From: Douglas  Read Replies (1) of 123
 
I wonder how the market will perceive this information? It would seem that Anergen has enough cash to last another year at their present burn rate. I have to commend the management staff for being proactive and realizing that they need to reduce costs. Most biotechnology companies seem to wait till all cash is gone before restructuring. I still wonder if their manpower count is still to high at 60!

It would seem that if the Phase I trial for AnergiX(TM) won't be over till the third quarter of this year then Novo Nordisk is probably correct in saying that they are just changing their strategic direction and not a lack of confidence in AnergiX(TM). At least Novo will pay for the Phase I expenses. This should give Anergen time to find another collaborator.

Do you know when or if Anergen has started a Phase III for their AnervaX(TM)?

Thanks,
Doug.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News